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Purpose: Acute exacerbations of COPD (AECOPD) are associated with pulmonary/systemic 
changes; however, quantification of those changes during AECOPD managed on an outpatient 
basis and factors influencing recovery are lacking. This study aimed to characterize patients’ 
changes during AECOPD and identify factors influencing their recovery.
Methods: Body mass index, the modified British Medical Research Council questionnaire, 
number of exacerbations in the previous year, and the Charlson comorbidity index (independent 
variables) were collected within 24–48 hours of hospital presentation (T0). Peripheral oxygen 
saturation (SpO
2
), forced expiratory volume in one second, percentage predicted (FEV
1
% pre-
dicted), maximum inspiratory pressure, quadriceps muscle strength, 5 times sit-to-stand, and 
COPD assessment test (CAT) (dependent variables) were collected at T0 and approximately at 
days 8 (T1), 15 (T2), and 45 (T3) after T0.
Results: A total of 44 outpatients with AECOPD (31♂; 68.2±9.1 years; 51.1±20.3 FEV
1
% 
predicted) were enrolled. All variables improved overtime (P,0.05); however, at day 8, only 
SpO
2
 and CAT (P#0.001) showed significant improvements. Changes in FEV
1
% predicted 
and SpO
2
 were not influenced by any independent measure, while changes in other outcome 
measures were influenced by at least one of the independent measures. Independently of the time 
of data collection, being underweight or overweight and having increased dyspnea, previous 
exacerbations, and severe comorbidities negatively affected patients’ outcomes.
Conclusion: FEV
1
% predicted and SpO
2
 were not influenced by any independent measure and, 
thus, seem to be robust measures to follow-up outpatients with AECOPD. No single indicator 
was able to predict patients’ recovery for all measures; thus, a comprehensive assessment at 
the onset of the AECOPD is required to personalize interventions.
Keywords: COPD exacerbations, management, outcome measures, outpatients
Introduction
COPD is frequently punctuated by acute exacerbations (acute exacerbations of COPD 
[AECOPD]), which account for more than half of the hospitalizations1 in COPD and 
are the main responsible for patients’ clinical deterioration and increased health care 
costs.2 Globally, more than 50% of COPD-related costs are due to AECOPD3 and in 
USA, costs are estimated in $7.100 per patient/exacerbation.4
Long-term consequences of AECOPD are known, such as clinical important 
physiological and functional deteriorations,2 resulting in significant declines in lung 
function, muscle strength, and quality of life and increased mortality.2,5 AECOPD are 
also responsible for significant patients’ clinical deterioration during its time course; 
however, most of the information available is on lung function and dyspnea6–8 in 
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hospitalized patients.5,7,9–11 Little information is still avail-
able on more functional parameters, such as muscle strength, 
activities of daily living, and impact of the disease. Moreover, 
hospitalized patients differ from outpatients not only in their 
management but also in the disease severity,12 which may 
influence their pattern of recovery. Thus, understanding 
outpatients’ recovery seems crucial to timely manage and 
appropriately plan their follow-ups.
Factors associated with the progression and prognosis of 
AECOPD during hospitalizations have already been studied 
and include patients’ anthropometrics, stage of the disease 
(according to dyspnea and number of AECOPD in the previ-
ous year), severity of comorbidities, and acute physiological 
derangements.13 Such information is essential to design man-
agement strategies and discharge plans during hospital stay. 
However, more than 80% of AECOPD are managed on an 
outpatient basis12 and knowledge on factors influencing the 
time course of AECOPD managed in this setting is scarce. 
This unawareness impairs the standardization, optimization, 
and personalization of the treatment and ultimately contrib-
utes to the existing high rate of AECOPD relapses.14
This study aimed to characterize patients’ lung function, 
oxygen saturation, muscles strength, impact of the disease, 
and functionality during the time course of AECOPD man-
aged on an outpatient basis. Additionally, it was aimed to 
identify the factors influencing this recovery period.
Methods
study design and participants
A longitudinal observational study was conducted in non-
hospitalized patients with AECOPD recruited from the 
urgent care of a Central Hospital. Inclusion criteria were the 
diagnosis of an AECOPD according to the GOLD criteria.12 
Exclusion criteria were hospitalization (defined as the need 
to be admitted as an inpatient at the respiratory or intensive 
care unit for further assessment/treatment after consultation 
with the urgency clinician); patients requiring emergency 
intubation and/or mechanical ventilation; and patients 
with compromised neurological status or hemodynamic 
instability or presence of severe co-existing respiratory, 
neurological (eg, Parkinson’s disease), cardiac (eg, uncon-
trolled symptomatic heart failure), musculoskeletal (eg, 
kyphoscoliosis), or signs of psychiatric impairments. Eligible 
patients were identified by clinicians and contacted by the 
researchers to schedule an appointment within 48 hours of 
the hospital visit.
Approval was obtained from the ethics committee of the 
Centro Hospitalar do Baixo Vouga (13NOV’1514:40065682) 
and from the National Data Protection Committee (8828/2016). 
Written informed consent was obtained before data 
collection.
sample size
In order to test the time effect (four measurements) over 
quantitative variables, a sample size estimation was per-
formed to detect moderate effect sizes (f=0.25) as signifi-
cant, with 80% power, 5% significance level. The minimum 
sample size estimated was 35 participants. In health-related 
longitudinal studies, dropout rates are of approximately 
20%–45%;15,16 thus, 44 participants with AECOPD were 
aimed to be recruited.
Data collection
Patients were asked to attend to the following four assess-
ment sessions: within 48 hours of the urgent care visit (T0, 
exacerbation onset) and approximately 8 days (T1, during 
exacerbation), 15 days (T2, following exacerbation),7 and 
45 days after the hospital visit (T3, at stability postexacerba-
tion). Data were collected at the urgent care, in the facilities 
of the University of Aveiro, or at patients’ home.
Sociodemographic (age and gender), anthropometric 
(height, weight, and body mass index [BMI]), and general 
clinical (smoking habits, number of exacerbations in the 
previous year, medication, comorbidities, and dyspnea) data 
were first collected. The severity of comorbid diseases was 
recorded and scored according to the Charlson comorbidity 
index (CCI).17 Dyspnea was assessed with the modified British 
Medical Research Council (mMRC) questionnaire.18
In each data collection moment, peripheral oxygen satu-
ration (SpO
2
), collected with a pulse oximeter (Pulsox 300i; 
Konica Minolta, Tokyo, Japan), lung function, respiratory 
muscle strength, quadriceps muscle strength (QMS), impact 
of the disease, and functionality were collected by a physio-
therapist following the described standardized order.
Impact of the disease was measured with the COPD 
assessment test (CAT), a disease-specific questionnaire with 
eight items (ie, cough, sputum, chest tightness, breathlessness 
going up hills/stairs, activity limitations at home, confidence 
leaving home, sleep, and energy).23
Lung function was assessed with a portable spirometer 
(MicroLab 3535; CareFusion, Kent, UK),19 and respiratory 
muscle strength was measured at the mouth as maximum 
inspiratory pressure (PImax) using an electronic pressure 
transducer (MicroRPM; Micromedical, Kent, UK)20 accord-
ing to the European Respiratory Society and American 
Thoracic Society guidelines.
QMS was measured as quadriceps peak torque during 
an isometric contraction of the quadriceps of the dominant 
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side with a handheld dynamometer (microFET2; Hoggan 
Health, Salt Lake City, Utah).21 The best of three acceptable 
and reproducible maneuvers was considered for analysis. 
Quadriceps peak torque was calculated in the percentage of 
predicted (QMS% predicted).22
Functionality was assessed with the 5 times sit-to-stand 
test (5STS). A straight-backed armless chair with a hard 
seat stabilized against a wall was used, and the protocol of 
Jones et al24 was followed. The best of three acceptable and 
reproducible maneuvers was considered for analysis.
statistical analyses
All statistical analyses were performed using IBM SPSS 
Statistics 24.0 (IBM Corporation, Armonk, NY, USA), and 
plots were created using GraphPad Prism 5.01 (GraphPad 
Software, Inc., La Jolla, CA, USA). The level of significance 
was set at 0.05.
Descriptive statistics was used to describe the sample. 
The evolution of each dependent variable during AECOPD 
and the identification of variables that could influence the 
evolution of the dependent variables were analyzed with 
generalized estimating equation’ (GEE) models with a 
gama link function and independent correlation structure. 
This method is an extension of generalized linear models to 
longitudinal data permitting the inclusion of time-dependent 
variables and the analysis of incomplete data (without 
imputing missing data), common in longitudinal health 
studies.25
To explore the influence of time independently, a first 
analysis was performed using SpO
2
, FEV
1
 percentage 
predicted (FEV
1
% predicted), PImax, QMS% predicted, 
CAT, and 5STS as dependent variables and time as the 
only independent variable. Then, to identify variables that 
could influence the evolution of the dependent variables, 
BMI (ie, underweight ,18.50, normal weight ,24.99, and 
overweight $25.00),26 number of exacerbations in the previ-
ous year (ie, 0–1 and $2),17 comorbidities (mild: CCI #2, 
moderate: CCI #4, and severe: CCI $5),17 and dyspnea 
(mild: mMRC ,2 and severe: mMRC $2)12 were included 
as independent variables. A clinical criterion was used to 
select the dependent and independent variables included in 
the models (variables commonly reported and associated 
with the response to treatments in COPD and with AECOPD 
in the literature).13,27–29
Results
Participants
Seventy-eight nonhospitalized patients with AECOPD 
were referred for possible inclusion in the study. Of whom, 
34 patients were excluded because at T0 they had a pul-
monary function and clinical history incompatible with a 
diagnosis of COPD (n=22), did not meet the definition for 
AECOPD (n=1), presented lung neoplasia (n=2) and severe 
heart failure (n=1), were unable to comply with testing 
(n=3), and showed decline to participate in the study (n=5). 
Forty-four nonhospitalized patients with AECOPD (31♂; 
68.18±9.09 years; 51.11±20.27 FEV
1
% predicted) were 
invited and agreed to participate in the study. Participants’ 
characteristics are summarized in Table 1.
Time course of aeCOPD
The variation of each variable within the time course of 
the AECOPD is found in Figure 1. At day 8, only SpO
2
 
and CAT (P#0.001) have shown significant improve-
ments. At day 15, FEV
1
% predicted (P=0.007) and 5STS 
(P,0.001) had improved from the onset of the AECOPD 
and at day 45, all variables presented significant improve-
ments (P,0.05). A detailed description of the variables 
analyzed per moment of data collection is found in 
Tables S1 and S2.
Factors influencing recovery from 
aeCOPD
Complete results of the independent variables’ (ie, BMI, 
number of exacerbations in the past year, CCI, and mMRC) 
effects in each of the dependent variables (ie, SpO
2
, FEV
1
% 
predicted, PImax, QMS% predicted, CAT, and 5STS) are 
found in Table S3.
Peripheral oxygen saturation
No significant interactions were found between the inde-
pendent variables and SpO
2
 (P.0.05). However, patients 
presenting two or more AECOPD had mean values of 
SpO
2
 lower than those with one or no AECOPD (mean 
difference -1.56%±0.53%; P=0.003) independently of the 
moment of data collection. Other independent variables 
were not found to significantly affect SpO
2
 (P.0.05) 
(Figure S1).
FeV1% predicted
No significant interactions were found between the indepen-
dent variables and FEV
1
% predicted (P.0.05). However, 
underweight patients presented lower FEV
1
% predicted than 
overweight (mean difference -18.98%±4.49% predicted) 
and normal weight (mean difference -17.84%±4.15% 
predicted) patients, independently of the moment of data 
collection (P,0.001). Other independent variables were 
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not found to significantly affect FEV
1
% predicted (P.0.05) 
(Figure S2).
PImax
Significant interactions between time and number of exacerba-
tions in the previous year (P=0.007), comorbidities (P=0.025), 
and dyspnea (P=0.012) were found to affect changes in PImax 
during AECOPD. Other independent variables were not found 
to significantly affect PImax (P.0.05) (Figure S3).
QMs% predicted
Significant interactions between time and number of exac-
erbations in the previous year (P=0.035) and comorbidities 
(P=0.020) were found to affect changes in QMS% predicted 
during AECOPD. Additionally, QMS% predicted was lower 
in more dyspneic patients (mMRC $2) than in less dyspneic 
patients (mMRC ,2; mean difference -24.27%±11.74% 
predicted; P=0.011), independently of the moment of data 
collection. Other independent variables were not found to sig-
nificantly affect QMS% predicted (P.0.05) (Figure S4).
CaT
Significant interactions between time and BMI (P=0.039) 
were found to affect changes in CAT during AECOPD. 
Additionally, CAT scores were higher in overweight patients 
(BMI $25) than in patients with normal BMI (mean differ-
ence 4.59±1.77; P=0.042) and in more dyspneic patients 
(mMRC $2; mean difference 7.98±1.84; P,0.001), inde-
pendently of the moment of data collection. Other indepen-
dent variables were not found to significantly affect CAT 
(P.0.05) (Figure S5).
5sTs
Significant interactions between time and BMI (P=0.008), 
comorbidities (P=0.001), and dyspnea (P=0.003) were found 
to affect changes in 5STS during AECOPD. Additionally, 
patients with severe comorbidities took longer to complete 
the 5STS than those with mild (mean difference 2.72±1.35) 
and moderate (mean difference 2.73±1.14) comorbidities 
in the CCI independently of the moment of data collection 
(P=0.013). Other independent variables were not found to 
significantly affect 5STS (P.0.05) (Figure S6).
Discussion
This study added important findings on the time course of 
AECOPD managed on an outpatient basis, namely: 1) SpO
2
 
and CAT improve after 7 days of the onset of an AECOPD, 
FEV
1
% predicted and 5STS improve after 15 days, and 
Table 1 sample characterization
Characteristics Patients with
AECOPD
(n=44)
age, years 68.18±9.09
gender (male), n (%) 31 (70.5)
BMI (kg/m2) 25.86±4.83
smoking status, n (%)
Current 8 (18.2)
Former 22 (50.0)
never 14 (31.8)
Packs/year 45.00 (22.00–67.25)
exacerbations (previous year), n (%)
0 8 (18.2)
1 11 (25.0)
$2 25 (56.8)
FeV1 (l) 1.22±0.51
FeV1% predicted 51.11±20.27
FeV1/FVC (%) 50.47±13.64
gOlD stages, n (%)
a 6 (13.6)
B 5 (11.4)
C 5 (11.4)
D 26 (59.1)
Medication, n (%)
antibiotics 28 (65.1)
Bronchodilators
saBa 9 (20.9)
saMa 6 (14.0)
saBa/saMa combination 6 (14.0)
laBa 5 (11.6)
laMa 22 (51.2)
laBa/laMa combination 5 (11.6)
ICs 7 (16.3)
ICs/laBa combination 27 (62.8)
Xanthines 16 (37.2)
lTra 4 (9.3)
expectorants 20 (46.5)
Oral corticosteroids 9 (20.9)
CCI
Mild 6 (14)
Moderate 25 (57)
severe 13 (29)
mMrC 1 (0.5–2.0)
Notes: Values are presented as mean ± sD (for normal distributed variables), or 
median (interquartile range) (for non-normal distributed variables) at T0, unless 
otherwise stated. FeV1, at stability – T3; FVC, at stability – T3.
Abbreviations: aeCOPD, acute exacerbations of COPD; BMI, body mass index; 
CCI, Charlson comorbidity index; ICs, Inhaled corticosteroid; laBa, long-acting 
beta-agonist; laMa, long-acting muscarinic antagonist; lTra, leukotriene receptor 
antagonist; saBa, short-acting beta-agonist; saMa, short-acting muscarinic 
antagonist; gOlD, global Initiative for Chronic Obstructive lung Disease; mMrC, 
Modified British Medical Research Council questionnaire; FEV1, forced expiratory 
volume in one second; FVC, forced vital capacity. 
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muscle strength improve after 45 days of the AECOPD; 
2) changes in SpO
2
 and FEV
1
% predicted are not influenced 
by BMI, dyspnea, previous AECOPD, or comorbidities; 
however, changes in other outcome measures were influenced 
by at least one independent variable; and 3) independently 
of the time of data collection, low/high BMI, increased 
dyspnea, previous exacerbations, and severe comorbidities 
significantly affect patients’ outcomes during AECOPD.
Most burdensome symptoms and limitations perceived 
by each patient improved in the first week (difference of 
approximately five points in CAT), exceeding the minimal 
clinical important difference (MCID) of two points,30,31 
and minor improvements were observed in the following 
weeks. These results matched those previously reported 
in hospitalized patients,10,32 in which major improvements 
have been obtained during the first 5 days of hospital 
admission.10 Improvements in CAT exceeding the MCID 
(from -3 to -1030,33) have been shown, with higher magni-
tudes observed in more severe exacerbations and in hospi-
talized patients.10 Assessment of CAT, especially in the first 
week following the AECOPD, is important, and different 
MCID might be needed for hospitalized and nonhospitalized 
Figure 1 Changes in (A) peripheral oxygen saturation (spO2, %), (B) FeV1% predicted, (C) PImax (cmh2O), (D) QMs% predicted, (E) CaT, and (F) 5sTs test (seconds).
Note: *Significantly different from T0 (P,0.05).
Abbreviations: CaT, COPD assessment test; PImax, maximum inspiratory pressure; QMs% predicted, quadriceps muscle strength percentage predicted; 5sTs, 5 times 
sit-to-stand test.
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patients with AECOPD. Additionally, a negative effect of 
overweight in CAT has been found, mimicking previous 
studies conducted in inpatients.10 These results shown that, 
independently of the setting of treatment, an excess of 
weight significantly impairs patients’ improvements in their 
health status.
The use of SpO
2
 and lung function to monitor patients 
with AECOPD have been controversial, as these measures 
have shown poor reliability and/or sensitivity to change.34,35 
Several studies have used SpO
2
 as an outcome measure; 
however, the changes reported vary widely8,36,37 and, in the 
absence of an MCID for this parameter, it is not clear whether 
these changes are clinically significant, especially in patients 
not presenting hypoxemia at baseline assessment. Lung 
function measurements during AECOPD are not currently 
recommended by the GOLD;35 however, they are widely 
used.7,8,11 Results previously obtained are not homogeneous 
with some authors reporting improvements in lung func-
tion, namely FEV
1
,7,8 and others finding no improvements 
after an AECOPD,11 which impairs conclusions regarding 
its usefulness and responsiveness during exacerbations. 
Using the minimal detectable difference recommended by 
the European Respiratory Society (ie, increment of 9% in 
FEV
1
% predicted),38 important improvements in FEV
1
 were 
only achieved at T3 (mean difference 9.3% from T0), mean-
ing that, at stability, most patients may have achieved full 
recovery. These results should nonetheless be interpreted 
with caution as the minimal detectable difference used has 
only been established for bronchodilator responsiveness in 
stable patients with COPD.38 Nevertheless, our study showed 
that both SpO
2
 and lung function are outcomes that can be 
simply obtained and seem not to be influenced by independent 
variables. Future studies are needed to further assess their 
adequacy to be used in monitoring AECOPD and establish 
their MCID.
Changes in muscle strength measures, such as PImax 
and QMS% predicted, were only significant after 45 days of 
AECOPD, and the pattern of their recovery was influenced 
by several independent measures, ie, dyspnea, previous 
exacerbations, and comorbidities. Recovery of physical 
parameters is often impaired during AECOPD and may never 
fully recover.2 In hospitalized patients, decreases in muscle 
strength occur even during the course of AECOPD,5 which 
was not observed in this study, possibly because patients 
continued to perform their daily activities at home, even if 
at a slower pace. The inclusion of strengthening exercises 
in hospitalized patients during AECOPD has been recom-
mended to further enhance their recovery.5 This addition 
may be equally valid and fruitful in outpatients, since it may 
fasten patients’ functional recovery to perform their daily 
and job-related activities.
Generally, more dyspneic patients, under-/overweight, 
with more exacerbations/year and more comorbidities, 
recovered slower, except for QMS and 5TST. These findings 
may be justified by the fact that these more fragile patients 
presented poorer values at baseline and, thus, had more room 
for improvement. In the 5STS test, at T0 the overall sample 
completed the test in .10 seconds, leaving them a marginal 
room for progress.24,39 This suggests that the 5STS presents 
a ceiling effect and may not be the most adequate outcome 
measure to monitor functionality in more functional patients 
but may be suitable for more severe and older patients.
Independently of the time of data collection, underweight 
patients presented more airway obstruction; overweight 
patients presented higher impacts of the disease; dysp-
neic patients presented lower QMS; frequent exacerbators 
presented lower oxygenation values; and patients with more 
comorbidities performed worse in 5STS. It is known that 
all of these parameters are potential predictors of COPD 
trajectory,28 and thus, it was expected that they would also 
play a role during the recovery of AECOPD. Nevertheless, 
it was not possible to find one single independent variable 
that influenced and differentiated improvements in all out-
come measures. These results further highlight the multi-
dimensional and systemic component of AECOPD and the 
importance of studying the role of emerging biomarkers,40,41 
together with clinical variables, to predict the trajectory of 
COPD, and specifically AECOPD.
Limitations
This study has some limitations that must be acknowledged. 
First, as effects of therapies were not of interest in this study, 
all patients were treated according to clinicians’ best judg-
ment. However, it must be acknowledged that different com-
binations of treatments might have influenced the outcomes 
of individual patients. Second, although a sample calculation 
has been computed to test the time effects in the dependent 
variables studied, the study was not powered for its second-
ary analysis (ie, identify the factors influencing this recovery 
from AECOPD), resulting in a possible small sample size 
for this analysis. Consequently, patients’ distribution among 
categories of independent variables (eg, BMI – underweight, 
normal weight, and overweight) were not homogeneous, 
which could have affected the results observed. Additionally, 
other variables that are known to influence COPD trajectory 
and that could also play a role in the time course of AECOPD, 
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such as forced vital capacity, medication, and nature of previ-
ous exacerbations, could not been integrated in the models 
developed. Increasing the number of independent variables 
would have augmented the risk of having correlations among 
the variables and, thus, decreased the robustness and the 
accuracy of the models. Further studies, powered for a high 
number of variables, should clarify the role of the clinical 
variables explored and consider their potential interaction 
with other demographic, chemical, and biological variables 
to better understand the time course of AECOPD managed on 
an outpatient basis. Although this was not the main objective 
of the present article, our exploratory results are valuable, 
as they contributed to unravel the most promising variables 
to assess in clinical practice and may be used to compute 
appropriate sample sizes in future research. Third, most 
outcome measures used depend on patients’ motivation and 
evaluator expertise. To minimize these influences, a trained 
physiotherapist conducted all data collection and only varia-
tions of less than 20% between the two better results (except 
for lung function and inspiratory muscle strength, where 
the European Respiratory Society and American Thoracic 
Society guidelines19,20 were followed) in each measurement 
were considered for analysis. Finally, patient’s stable state 
prior to the exacerbation was not assessed and, thus, it is 
not known if patients returned or not to their baseline status. 
Still, information of the course of exacerbations managed 
on an outpatient basis is still provided and may be useful to 
personalize interventions in this population.
Conclusion
During an AECOPD managed on an outpatient basis, SpO
2
 
and CAT improve after 7 days of the onset, FEV
1
% pre-
dicted and 5STS improve after 15 days, and muscle strength 
measures improved only after 45 days of the AECOPD. 
FEV
1
% predicted and SpO
2
 recovery are not influenced by 
independent patients’ characteristics, such as BMI, dyspnea, 
previous AECOPD, or comorbidities and, thus, may be 
potentially useful to monitor AECOPD recovery. Low/high 
BMI, increased dyspnea, previous exacerbations, and severe 
comorbidities significantly affect patients’ outcomes during 
AECOPD. No single indicator was able to predict patients’ 
recovery for all measures assessed; thus, a comprehensive 
assessment at the onset of the AECOPD is needed to person-
alize interventions to outpatients with AECOPD.
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